At OCT DACH 2025, industry members noted that the implementation of AI in clinical trials must be carefully thought out.

Gene anticipates filing a biologics licence application (BLA) for detalimogene voraplasmid to the FDA in H2 2026.

If Roche's fenebrutinib got the FDA go-ahead, it would become the first BTK inhibitor to gain approval in both RMS and PPMS.

Alkermes announced that the drug met its dual primary endpoints, however this was only in the two high dose cohorts and the data was “adjusted for multiplicity”. Image credit: MediaNews Group / Boston ...

Eli Lilly will advance eloralintide to Phase III trials in obesity. Image credit: Michael Vi / Shutterstock.com Eli Lilly is advancing its obesity treatment candidate, which is an alternative to ...

If approved in AFRS, it would become the ninth US approved indication for Dupixent. Image credit: Angelina Avei / Shutterstock.com Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ...